Free Trial
NASDAQ:LENZ

LENZ Therapeutics 11/13/2023 Earnings Report

LENZ Therapeutics logo
$40.53 -0.73 (-1.77%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$40.88 +0.35 (+0.86%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENZ Therapeutics EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

LENZ Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

LENZ Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

LENZ Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

LENZ Therapeutics Earnings Headlines

Jim Cramer Says “LENZ Therapeutics Has a Promising Story”
Jim Cramer’s Recent Takes on These 12 Stocks
China’s message to Trump
Did China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of military power. Fighter jets, tanks, AI-guided drones — all paraded under the red flag, in front of Vladimir Putin, Kim Jong Un, and more than two dozen world leaders.tc pixel
See More LENZ Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENZ Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENZ Therapeutics and other key companies, straight to your email.

About LENZ Therapeutics

LENZ Therapeutics (NASDAQ:LENZ), a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

View LENZ Therapeutics Profile

More Earnings Resources from MarketBeat